Result for
Topic: Vaccines and Immunity
May 28, 2021
The Humoral Response to the BNT162b2 Vaccine in Hemodialysis Patients
[Pre-print, not peer-reviewed] Anti-SARS-CoV-2 spike antibodies were detected in 80% of chronic hemodialysis patients (n=66) 28 days after a single dose of the Pfizer-BioNTech vaccine in a cohort study in Toronto, Canada. However, only 23% mounted a robust response defined by exceeding the median level of anti-spike antibodies observed in serum of healthy convalescent controls…
Reduced Sensitivity of Infectious SARS-CoV-2 Variant B.1.617.2 to Monoclonal Antibodies and Sera from Convalescent and Vaccinated Individuals
[Pre-print, not peer-reviewed] The SARS-CoV-2 B.1.617.2 variant of concern, first described in India, was experimentally shown to completely escape neutralizing activity from the monoclonal antibody (mAb) bamlanivimab (made by Eli Lilly), while neutralizing activity of etesivimab (also Eli Lilly), casirivimab and imdevimab (Regeneron) were preserved. Neutralizing activity of sera from 56 individuals recovered from critical,…
Seroprevalence of SARS-CoV-2 Antibodies in Seattle, Washington: October 2019–April 2020
Residual clinical samples collected from 766 Seattle-area adults during October 2019 to April 2020 showed that anti-SARS-CoV-2 antibodies were not detected until mid-March 2020. Estimated antibody prevalence from March 5-April 1, 2020 was 1.2%, which was 11 times greater than the number of confirmed cases in King County, which includes Seattle, as of April 1….
Risk of Reinfection after Seroconversion to SARS-CoV-2: A Population-Based Propensity-Score Matched Cohort Study
Swiss adults who were seropositive for SARS-CoV-2 IgG antibodies were less likely to have a SARS-CoV-2 PCR positive test than propensity-score-matched seronegative adults in the 8 months following antibody measurements. Of the 498 seropositive individuals, only 5 (1%) retested positive (likely indicative of reinfection) after a mean follow-up of 36 weeks. In contrast, 154 of…
E484K as an Innovative Phylogenetic Event for Viral Evolution: Genomic Analysis of the E484K Spike Mutation in SARS-CoV-2 Lineages from Brazil
Genomic and phylogenetic analyses of SARS-CoV-2 genomes with the E484K mutation sequenced from samples in Brazil in 2020 showed that over 40% of sequenced genomes had this mutation by October 2020 across three distinct lineages (P.1, P.2, and N.9) in four different regions. Modeling of a random set of sequenced genomes suggests that the mutation…
Effectiveness of BNT162b2 and MRNA-1273 COVID-19 Vaccines against Symptomatic SARS-CoV-2 Infection and Severe COVID-19 Outcomes in Ontario Canada
[Pre-print, not peer-reviewed] COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) were 60% effective against symptomatic SARS-CoV-2 infection 14-20 days after the first dose and 91% effective ≥7 days after the second dose in a test-negative study among symptomatic adults in Ontario, Canada between December 2020 and April 2021 (n=324,033). Vaccine effectiveness against severe outcomes was 62%…
Patterns in COVID-19 Vaccination Coverage, by Social Vulnerability and Urbanicity — United States, December 14, 2020–May 1, 2021
As of May 1, 2021, vaccination coverage was lower among US adults living in counties with higher social vulnerability (social and structural factors associated with adverse health outcomes) and with higher percentages of households with children, single parents, and persons with disabilities. By May 1, vaccination coverage was lower among adults living in counties with…
May 27, 2021
Accessibility and Usability of State Health Department COVID-19 Vaccine Websites
A qualitative evaluation of each US state’s department of health website content for vaccine eligibility and availability conducted in February 2021 found that of the 47 states providing eligibility information, 57% did not support eligibility verification, and 83% presented eligibility information at a post-high school reading level. Only half of all states provided web-based appointment…
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
A randomized trial of the Pfizer-BioNTech vaccine (BNT162b2) among adolescents ages 12-15 reported vaccine efficacy of 100% (75.3-100%) against COVID-19 for the 2-dose vaccine series. There were 16 cases of COVID-19 among 1,129 placebo recipients and no COVID-19 cases among 1,131 vaccine recipients that occurred 7 or more days after the second dose among participants…
Cellular and Humoral Response after MRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients
Only 35 of 117 (30%) kidney transplant recipients without known prior SARS-CoV-2 infection had a detectable humoral immune response (anti-spike IgG and/or IgM antibodies) to the Moderna vaccine two weeks after the second dose, while 55% had a detectable cellular immune response. Development of both humoral and cellular immune responses was observed in 20% of…
Previous page Next page